DUBLIN--(BUSINESS WIRE)--The "Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
"Non-Alcoholic Steatohepatitis (NASH) - Pipeline Insight, 2019 report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Non-Alcoholic Steatohepatitis (NASH) development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Inactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for Non-Alcoholic Steatohepatitis (NASH)
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Pipeline Therapeutics assessment of products for Non-Alcoholic Steatohepatitis (NASH)
The report assesses the active Non-Alcoholic Steatohepatitis (NASH) pipeline products by developmental stage, product type, molecule type, and administration route.
Key Topics Covered:
1. Report Introduction
2. Non-Alcoholic Steatohepatitis (NASH) Overview
3. Pipeline Therapeutics
4. Comparative Analysis
5. Products in Clinical Stage
6. Products in Pre-Clinical and Discovery Stage
7. Therapeutic Assessment
8. Inactive Products
- Albreo Pharma Inc
- Allergan Plc
- Alnylam Pharmaceuticals Inc
- Amunix Operating Inc
- Aquinox Pharmaceuticals Inc
- Ardelyx Inc
- Arisaph Pharmaceuticals Inc
- ARMO Biosciences Inc
- AstraZeneca Plc
- Betagenon AB
- BioLineRx Ltd
- BiOrion Technologies BV
- Bird Rock Bio Inc
- Boehringer Ingelheim GmbH
- BLR Bio LLC
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/rh55k5/nonalcoholic?w=4